Pharmacokinetics of recombinant interferon alpha-C

Ofer Merimsky; Menachem Rubinstein; Dina Fischer; Abraham Danon; Samario Chaitchik

doi:10.1007/BF00688867

Pharmacokinetics of recombinant interferon alpha-C

Ofer Merimsky, Menachem Rubinstein, Dina Fischer, Abraham Danon, Samario Chaitchik

Basic Sciences Divisions

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Recombinant interferon alpha-C (rIFNα-C, Interpharm), is a new type of alpha-interferon that has a specific activity of 1-2×10⁹ units/mg protein. The pharmacokinetics of rIFNα-C were studied in 11 patients with metastatic renal-cell carcinoma. A total of 10 million units IFNα-C were injected intramuscularly and the serum level of IFN was evaluated up to 72 h post-administration. Measurable IFN concentrations appeared in the serum as early as 0.5 h, and levels peaked at 4-6 h (C_max=53.2±4.6 units/ml). Relatively high levels persisted for 24 h and declined thereafter with an apparent half-life of 3-4 h. The mean area under the serum-concentration curve (AUC) was 1,259±145 units h ml^-1, indicating good bioavailability of the preparation from the intramuscular injection.

Original language	English
Pages (from-to)	406-408
Number of pages	3
Journal	Cancer Chemotherapy and Pharmacology
Volume	27
Issue number	5
DOIs	https://doi.org/10.1007/BF00688867
State	Published - 1 Sep 1991

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF00688867

Cite this

@article{613b4920a8a2486aadd2317e7699157c,

title = "Pharmacokinetics of recombinant interferon alpha-C",

abstract = "Recombinant interferon alpha-C (rIFNα-C, Interpharm), is a new type of alpha-interferon that has a specific activity of 1-2×109 units/mg protein. The pharmacokinetics of rIFNα-C were studied in 11 patients with metastatic renal-cell carcinoma. A total of 10 million units IFNα-C were injected intramuscularly and the serum level of IFN was evaluated up to 72 h post-administration. Measurable IFN concentrations appeared in the serum as early as 0.5 h, and levels peaked at 4-6 h (Cmax=53.2±4.6 units/ml). Relatively high levels persisted for 24 h and declined thereafter with an apparent half-life of 3-4 h. The mean area under the serum-concentration curve (AUC) was 1,259±145 units h ml-1, indicating good bioavailability of the preparation from the intramuscular injection.",

author = "Ofer Merimsky and Menachem Rubinstein and Dina Fischer and Abraham Danon and Samario Chaitchik",

year = "1991",

month = sep,

day = "1",

doi = "10.1007/BF00688867",

language = "English",

volume = "27",

pages = "406--408",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "5",

}

TY - JOUR

T1 - Pharmacokinetics of recombinant interferon alpha-C

AU - Merimsky, Ofer

AU - Rubinstein, Menachem

AU - Fischer, Dina

AU - Danon, Abraham

AU - Chaitchik, Samario

PY - 1991/9/1

Y1 - 1991/9/1

N2 - Recombinant interferon alpha-C (rIFNα-C, Interpharm), is a new type of alpha-interferon that has a specific activity of 1-2×109 units/mg protein. The pharmacokinetics of rIFNα-C were studied in 11 patients with metastatic renal-cell carcinoma. A total of 10 million units IFNα-C were injected intramuscularly and the serum level of IFN was evaluated up to 72 h post-administration. Measurable IFN concentrations appeared in the serum as early as 0.5 h, and levels peaked at 4-6 h (Cmax=53.2±4.6 units/ml). Relatively high levels persisted for 24 h and declined thereafter with an apparent half-life of 3-4 h. The mean area under the serum-concentration curve (AUC) was 1,259±145 units h ml-1, indicating good bioavailability of the preparation from the intramuscular injection.

AB - Recombinant interferon alpha-C (rIFNα-C, Interpharm), is a new type of alpha-interferon that has a specific activity of 1-2×109 units/mg protein. The pharmacokinetics of rIFNα-C were studied in 11 patients with metastatic renal-cell carcinoma. A total of 10 million units IFNα-C were injected intramuscularly and the serum level of IFN was evaluated up to 72 h post-administration. Measurable IFN concentrations appeared in the serum as early as 0.5 h, and levels peaked at 4-6 h (Cmax=53.2±4.6 units/ml). Relatively high levels persisted for 24 h and declined thereafter with an apparent half-life of 3-4 h. The mean area under the serum-concentration curve (AUC) was 1,259±145 units h ml-1, indicating good bioavailability of the preparation from the intramuscular injection.

UR - http://www.scopus.com/inward/record.url?scp=0026098903&partnerID=8YFLogxK

U2 - 10.1007/BF00688867

DO - 10.1007/BF00688867

M3 - Article

C2 - 1999003

AN - SCOPUS:0026098903

SN - 0344-5704

VL - 27

SP - 406

EP - 408

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 5

ER -

Pharmacokinetics of recombinant interferon alpha-C

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this